Compare · OCDX vs VNRX
OCDX vs VNRX
Side-by-side comparison of Ortho Clinical Diagnostics Holdings plc (OCDX) and VolitionRX Limited (VNRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OCDX and VNRX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- OCDX is the larger of the two at $4.08B, about 720.8x VNRX ($5.7M).
- VNRX has hit the wire 2 times in the past 4 weeks while OCDX has been quiet.
- OCDX has more recent analyst coverage (8 ratings vs 4 for VNRX).
- Company
- Ortho Clinical Diagnostics Holdings plc
- VolitionRX Limited
- Price
- -
- -
- Market cap
- $4.08B
- $5.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- AMEX
- IPO
- 2021
- 2015
- News (4w)
- 0
- 2
- Recent ratings
- 8
- 4
Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
VolitionRX Limited
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q Vet Cancer Screening Test for veterinary applications. The company also develops blood-based Nu.Q immunoassays to detect specific biomarkers. In addition, it is developing various veterinary products, including a treatment monitoring test, a disease recurrence test, and a point-of-care platform. VolitionRx Limited is based in Austin, Texas.
Latest OCDX
- SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc
- SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Busky Joseph M
- SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Palaniappan Chockalingam
- SEC Form 4: Yates Robert Clifton returned 323,880 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Christopher M returned 367,360 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Dilsaver Evelyn S returned 5,200 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Mac Mahon Thomas P returned 141,853 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Labrum Ronald K returned 109,985 units of Ordinary Shares to the company, closing all direct ownership in the company
Latest VNRX
- Chief Commercial Officer Forterre Gael covered exercise/tax liability with 284 shares, decreasing direct ownership by 2% to 16,284 units (SEC Form 4) (tax liability)
- Chief Operating Officer Michel Gaetan covered exercise/tax liability with 608 shares, decreasing direct ownership by 5% to 12,232 units (SEC Form 4) to cover withholding tax
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
- VolitionRx Participates in Launch of DETECSEPS Program in France
- VolitionRX Limited filed SEC Form 8-K: Unregistered Sales of Equity Securities
- VolitionRX Limited filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
- SEC Form EFFECT filed by VolitionRX Limited
- Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference